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Cutoff point 500 U/mL 78%, 73% . 31 Chi 500 U/mL cutoff point 1050 U/mL (Fig. 1, 2 . [35] [36] [37] , (1) (doubling time) , (2) (active growth phase) ,
. [4] [5] [6] .
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